$7.47
Today
as of Sep 4, 16:48 ET
Last 30 days
Recent Press Releases & News
Precision BioSciences Doses First Patient in Trial of Potential Duchenne Muscular Dystrophy Treatment
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences: Q2 Earnings Snapshot
Overview
52-week range
$3.53
$9.62
65% of range
Avg surprise (last 3)
-902.2%
Avg reaction (last 2)
-5.2%
0% positive
Latest IV / EM
207%
EM ±36.6% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.26 | — | — | — | — | financials |
| Tue May 5, 2026 | Mar/2026 | $-0.34 | $-0.27 | -25.9% | +84.6% | -2.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.84 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-2.13 | $-0.09 | -2,267% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-2.21 | $-0.43 | -413.9% | — | -8.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $4.67 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $1.70 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.10 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.13 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-6.75 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $11M | — | $13,000 | $18,000 | $29,000 | — | $576,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-19M | $-9M | — | $-21M | $-22M | $-22M | — | $-21M |
| Net income | $-33M | $-18M | — | $-22M | $-24M | $-21M | — | $-16M |
| EPS (diluted) | $-1.26 | $-0.75 | — | $-1.84 | $-2.13 | $-2.21 | — | $-2.25 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $86M | $99M | $111M | $45M | $62M | $77M | $86M | $99M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $92M | $109M | $119M | $52M | $70M | $82M | $95M | $111M |
| Total assets | $126M | $144M | $154M | $94M | $109M | $124M | $136M | $153M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $81M | $68M | $62M | $77M | $75M | $75M | $80M | $88M |
| Total equity | $45M | $76M | $92M | $17M | $34M | $49M | $56M | $65M |